Mercy BioAnalytics Appoints Diagnostics Industry Trailblazer Dr. Myla Lai-Goldman to Its Board of Directors

 
 

NATICK, Mass.--(BUSINESS WIRE)-- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of Myla Lai-Goldman, MD, to its Board of Directors.

“Myla’s visionary leadership and extensive experience in diagnostic development and laboratory testing will be another significant catalyst in Mercy’s journey to bring our diagnostic test portfolio to patients,” said Mercy BioAnalytics CEO Dawn Mattoon, PhD. “We are thrilled and honored to have a Director of Myla’s distinction join the Mercy Board as we advance our mission to save lives and relieve suffering through the early detection of cancer.”

Dr. Lai-Goldman is a diagnostics industry veteran, bringing decades of excellence in the development and commercialization of impactful clinical assays to Mercy’s Board. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical and Chief Scientific Officer. During her tenure at LabCorp, she led all clinical, scientific, and medical activities, including the introduction of more than 400 clinical assays, and led numerous licensing partnerships and acquisitions. Dr. Lai-Goldman is a co-founder and Chairperson of GeneCentric Therapeutics, where she previously served as President and CEO. Additionally, she is a venture partner with Hatteras Venture Partners and managing partner of Personalized Science, LLC, a diagnostic consulting company that she founded in 2008. In addition to GeneCentric, Dr. Lai-Goldman currently serves on the boards of West Pharmaceutical Services, Akoya Biosciences, Qvella Corporation, and NovoPath. Board-certified in both anatomic and clinical pathology, she received her medical degree from Columbia University College of Physicians and Surgeons.

“I am honored to join the Mercy Board and support the company’s efforts to advance their diagnostic test portfolio through clinical validation and entry into the market,” said Dr. Lai-Goldman. “Mercy’s innovative liquid biopsy platform is exceptionally well suited to the early detection of cancer, leveraging highly abundant tumor-derived extracellular vesicles to indicate the presence of even the smallest tumors. This groundbreaking approach has the potential to significantly reduce cancer-associated morbidity and mortality by enabling earlier intervention, improving the lives of patients and their families.”

ABOUT MERCY BIOANALYTICS

Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant, blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo platform is designed to detect Stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast and prostate cancers combined. For additional information, please visit https://www.mercybio.com.

Contacts

Michelle McAdam, Chronic Communications Inc.
michelle@chronic-comm.com
310.902.1274

 
 

Source: Mercy BioAnalytics, Inc.

Back to news